RenovoRx Reports Q3 2026 Revenue Growth and Maintains Full-Year Guidance
RenovoRx (RNXT) reported third-quarter revenue of $1.07 million, marking a 17% sequential increase and a fourfold increase year-over-year. This growth was primarily driven by the expansion of its active commercial cancer center network, which grew to 26 centers as of September 30, 2026. The company maintained its full-year 2026 revenue guidance of $3.75 million to $4.25 million, citing strong commercial momentum and a growing sales pipeline. Despite a net loss of $3.6 million ($0.08 per share), the company showed operational improvements, including a reduction in operating loss compared to the previous quarter. RenovoRx holds approximately $10.4 million in cash and cash equivalents, providing an estimated operational runway into the second half of 2027. Looking ahead, management aims to reach 36 active commercial centers by year-end and anticipates top-line data from its TIGeR-PaC trial in the second half of 2027.
Tickers: $SYRE
Topics: Commercial Expansion Financial Guidance Gross Margin Revenue Growth